bioRxivImmunologyPreprint
Immuno-proteomic interrogation of dengue infection reveals novel HLA haplotype-specific MHC-I antigens
K. Swaminathan, N. Olsson, P. J. Lund, C. D. Marceau, L. E. Wagar, Y. Tian, J. Sidney, D. Weiskopf, K. Majzoub, A. D. deSilva, E. Harris, M. M. Davis, A. Sette, J. E. Carette, J. E. Elias
Abstract
Broadly effective vaccines against dengue virus (DENV) infection have remained elusive, despite rising infection rates in the developing world. Infection-specific peptide ligands presented on Major Histocompatibility Complexes (MHC) open new avenues for developing T-cell-based interventions. Past efforts towards mapping viral MHC epitopes were based on computational predictions that only partially reflected actual antigen presentation. To empirically identify DENV-specific MHC ligands, we developed an immuno-proteomics approach for interrogating DENV- and self-derived MHC ligands from infected B-lymphocytes. Here, we report four fundamental findings: First, over 700 infection-specific MHC-ligands reflected host cellular responses to DENV that were not apparent from the proteome. Second, we report 121 viral MHC-I ligands (108 novel) which clustered into discrete hotspots across the DENV polyprotein, some of which spanned DENV polyprotein components, described here as MHC ligands for the first time. Third, we found DENV ligands which were distinctly presented by MHC alleles previously associated with either high or low anti-DENV response. Fourth, we demonstrate that while our in vitro assay only overlapped with a small fraction of previously described DENV T-cell epitopes, several novel MHC ligands identified here were recognized by T-cells from DENV-infected patients despite having low binding affinities. Together, these discoveries suggest that virus and host-derived MHC ligands have under-exploited potential for describing the cell biology of DENV infection, and as candidates for designing effective DENV vaccines.
- organism: virus
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Immunoinformatic approach to design CTL epitope based chimeric vaccine targeting multiple serotypes of dengue virus
Nilanshu Manocha, Prashant Kumar, Madhu Khanna·bioRxiv·Jan 15, 2024
- Targeting "Immunogenic Hotspots" in Dengue and Zika Virus: A Novel Approach to a Common Vaccine
D. Mahata, D. Mukherjee, … G. Mukherjee·bioRxiv·Jul 23, 2021
- An epitope-resurfaced virus-like particle can induce broad neutralizing antibody against four serotypes of dengue virus
Wen-Fan Shen, Jedhan Ucat Galula, … Day-Yu Chao·bioRxiv·Jun 20, 2018
- Dengue viruses serotypes 2 and 4 exhibit distinct infection kinetics and modulation of anti-viral immune responses in human tonsil histocultures
Rafael Fenutría, Laura Espinar‐Barranco, … Ana Fernández-Sesma·bioRxiv·May 10, 2026
- A dengue monovalent vaccine with novel structure provides cross-protection against four serotypes of dengue virus
Day-Yu Chao, Wen-Fan Shen, … Shang-Rung Wu·bioRxiv·Mar 5, 2018
- HLA upregulation during dengue virus infection suppresses the natural killer cell response
J. L. McKechnie, D. Beltran, … S. Lopez-Verges·bioRxiv·Jul 11, 2019